GlassScriptPhysician profile
Michael S Cohen
NPI 1467435081
$10,215.17
in general payments reported to CMS, 2019-2025
25 companies · $972 in 2025
The $972 reported for 2025 was more than what 86% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $622 · 2021: $2,052 · 2022: $952 · 2023: $2,914 · 2024: $2,182 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,300 · Travel and Lodging: $1,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,300.17 |
| Travel and Lodging | $1,767.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,905.66 | 2019-2025 | Xpress Ent Dilation System, Entellus Medical Focess Sinuscope, Scopis Ent |
| Medtronic, INC. | $1,645.45 | 2022-2024 | Sinuva, Propel |
| Aerin Medical INC. | $1,403.85 | 2021-2025 | |
| Genzyme Corporation | $886.40 | 2019-2025 | |
| Optinose US, INC. | $636.11 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $571.96 | 2019-2025 | Dupixent |
| Inspire Medical Systems, INC. | $329.16 | 2023-2024 | Inspire |
| Neurent Medical Limited | $327.54 | 2022-2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Intersect Ent, INC. | $309.82 | 2020-2022 | |
| Glaxosmithkline, LLC. | $307.58 | 2021-2023 | Nucala |
| Grifols USA, LLC | $168.60 | 2023-2025 | Xembify |
| Pfizer INC. | $142.17 | 2021-2024 | |
| Acclarent, INC | $126.48 | 2019-2021 | |
| Smith+Nephew, INC. | $62.69 | 2020-2024 | Tula |
| Hikma Pharmaceuticals USA | $57.42 | 2023-2024 | Ryaltris |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $53.46 | 2021-2023 | |
| Amgen INC. | $49.35 | 2025 | Tezspire |
| Kaleo, INC. | $45.88 | 2020-2022 | |
| Verity Pharmaceuticals INC. | $39.30 | 2025 | Tlando |
| Preceptis Medical, INC. | $37.31 | 2024 | Hummingbird Tympanostomy Tube System |
| Pharming Healthcare, INC. | $29.11 | 2024 | Ruconest |
| Invivyd INC | $24.57 | 2025 | Pemgarda |
| Lilly USA, LLC | $22.75 | 2025 | Zepbound |
| Xoran Technologies LLC | $18.04 | 2021 | |
| Baudax Bio INC. | $14.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.